OABI

+ Watchlist + Portfolio

OmniAb, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.19
52-Week Range: $1.30 – $4.59
Market Cap: $625.18M
P/E (TTM): —
EPS (TTM): -0.37
Dividend Yield: —

Advanced Metrics

Price/Book: 2.40
PEG Ratio: —
Return on Equity: -16.95%
Return on Assets: -8.35%
Gross Margin: 98.28%
Operating Margin: -49.47%
Profit Margin: -115.12%
Current Ratio: 4.80
Debt/Equity: 0.07
Total Debt: $18.91M
Free Cash Flow: $-285.00K
Revenue Growth: 244.20%
Earnings Growth: —
Enterprise Value: $592.10M

OABI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$59.08M	$34.16M	$26.39M	$18.67M
Cost of Revenue	—	—	$0.00	$303.00K
Gross Profit	—	—	$26.39M	$18.36M
Research & Development	$48.36M	$56.52M	$55.11M	$47.75M
Selling, General & Admin	$24.90M	$33.31M	$30.74M	$29.21M
Operating Expenses	$85.72M	$103.58M	$100.89M	$87.33M
Operating Income	-$26.65M	-$69.42M	-$74.50M	-$68.97M
EBITDA	-$8.40M	-$49.92M	-$50.92M	-$47.22M
Pretax Income	-$26.06M	-$64.36M	-$71.41M	-$66.29M
Income Tax	-$3.73M	-$13.74M	-$9.38M	-$1.51M
Net Income	-$22.33M	-$50.62M	-$62.03M	-$64.78M
Diluted EPS	-0.26	-0.51	-0.61	-0.57
Diluted Shares	85.32M	99.68M	102.36M	113.64M

OABI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$33.39M	$16.36M	$27.60M	$25.52M
Receivables	$30.29M	$3.84M	$5.27M	$7.39M
Current Assets	$124.95M	$94.90M	$68.14M	$65.34M
Total Assets	$421.21M	$375.23M	$325.56M	$300.91M
Current Liabilities	$26.02M	$23.12M	$15.09M	$16.25M
Total Debt	$25.80M	$25.56M	$23.16M	$20.33M
Total Liabilities	$79.84M	$60.64M	$37.94M	$33.89M
Retained Earnings	$11.25M	-$39.37M	-$101.40M	-$166.18M
Shareholders' Equity	$341.37M	$314.58M	$287.62M	$267.03M
Working Capital	$98.93M	$71.78M	$53.05M	$49.09M

OABI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.59M	$2.35M	-$39.66M	-$36.45M
Capital Expenditure	-$17.17M	-$1.64M	-$1.88M	-$565.00K
Free Cash Flow	-$20.75M	$703.00K	-$41.54M	-$37.02M
Depreciation & Amortisation	$18.25M	$19.50M	$23.58M	$21.75M
Stock-Based Compensation	$18.32M	$24.82M	$21.50M	$15.82M
Investing Cash Flow	-$73.31M	-$18.38M	$37.88M	$6.47M
Financing Cash Flow	$110.74M	-$892.00K	$13.02M	$27.91M
Net Change in Cash	$33.84M	-$16.92M	$11.24M	-$2.07M

OABI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$4.15M	$3.90M	$2.24M	$8.38M	$14.43M
Cost of Revenue	$3.00K	$262.00K	$29.00K	$9.00K	$15.00K
Gross Profit	$4.15M	$3.63M	$2.21M	$8.37M	$14.41M
Research & Development	$12.60M	$10.86M	$10.38M	$13.91M	$9.64M
Selling, General & Admin	$7.92M	$7.68M	$6.78M	$6.84M	$6.62M
Operating Expenses	$23.00M	$22.85M	$20.35M	$24.13M	$22.24M
Operating Income	-$18.84M	-$19.22M	-$18.14M	-$15.77M	-$7.83M
EBITDA	-$14.10M	-$14.57M	-$13.48M	-$8.06M	-$615.00K
Pretax Income	-$18.31M	-$15.76M	-$17.69M	-$14.55M	-$7.26M
Income Tax	-$106.00K	$119.00K	-$1.16M	-$367.00K	$442.00K
Net Income	-$18.20M	-$15.88M	-$16.52M	-$14.18M	-$7.71M
Diluted EPS	-0.17	-0.15	-0.14	-0.11	-0.06
Diluted Shares	105.62M	106.15M	114.73M	127.79M	128.25M

OABI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.89M	$18.28M	$28.54M	$25.52M	$29.05M
Receivables	$6.48M	$2.71M	$3.10M	$7.39M	$12.64M
Inventory	—	—	$443.00K	—	$920.00K
Current Assets	$53.58M	$47.62M	$66.35M	$65.34M	$65.13M
Total Assets	$306.18M	$295.67M	$309.69M	$300.91M	$293.65M
Current Liabilities	$11.41M	$12.64M	$13.28M	$16.25M	$13.57M
Total Debt	$22.48M	$21.78M	$21.07M	$20.33M	$19.67M
Total Liabilities	$32.67M	$33.61M	$32.25M	$33.89M	$31.00M
Retained Earnings	-$119.60M	-$135.47M	-$152.00M	-$166.18M	-$173.89M
Shareholders' Equity	$273.52M	$262.06M	$277.44M	$267.03M	$262.65M
Working Capital	$42.17M	$34.98M	$53.07M	$49.09M	$51.56M

OABI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$15.87M	-$5.15M	-$9.76M	-$5.67M	-$4.91M
Capital Expenditure	-$209.00K	-$165.00K	-$182.00K	-$9.00K	-$167.00K
Free Cash Flow	-$16.08M	-$5.31M	-$9.95M	-$5.68M	-$5.08M
Depreciation & Amortisation	$4.74M	$4.65M	$4.66M	$7.71M	$7.21M
Stock-Based Compensation	$4.14M	$4.11M	$3.96M	$3.61M	$3.34M
Investing Cash Flow	-$878.00K	$12.30M	-$7.67M	$2.71M	$8.44M
Financing Cash Flow	$44.00K	$236.00K	$27.68M	-$50.00K	$0.00
Net Change in Cash	-$16.71M	$7.39M	$10.26M	-$3.01M	$3.52M

Market Snapshot

About

OmniAb Inc. provides antibody discovery platforms for biopharmaceutical companies. The company offers transgenic animal and in vitro technologies that enable partners to discover and develop human therapeutic antibodies and other biologics.